Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

NCT04862741 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: NX-13 250mg IR
DRUG: NX-13 500mg IR
DRUG: NX-13 500mg MR
DRUG: Placebo

Sponsor

Landos Biopharma Inc.